Ralph R Weichselbaum Selected Research

N-(2-mercaptoethyl)-1,3-diaminopropane

2/2013	A manganese superoxide dismutase (SOD2)-mediated adaptive response.
5/2002	Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine.
1/2002	Inhibition of spontaneous metastases formation by amifostine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralph R Weichselbaum Research Topics

Disease

154	Neoplasms (Cancer) 01/2022 - 01/2002
49	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2002
16	Breast Neoplasms (Breast Cancer) 12/2020 - 11/2008
15	Head and Neck Neoplasms (Head and Neck Cancer) 09/2014 - 05/2002
11	Necrosis 12/2021 - 11/2002
10	Glioma (Gliomas) 12/2021 - 05/2002
9	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 12/2006
9	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 03/2004
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 02/2012
8	Bites and Stings (Sting) 01/2022 - 11/2014
8	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 05/2006
7	Inflammation (Inflammations) 01/2021 - 12/2007
7	Squamous Cell Carcinoma of Head and Neck 03/2017 - 04/2010
6	Adenocarcinoma 01/2019 - 08/2002
5	Melanoma (Melanoma, Malignant) 01/2022 - 01/2007
5	Hypoxia (Hypoxemia) 03/2019 - 01/2003
5	Carcinoma (Carcinomatosis) 01/2018 - 09/2004
5	Lung Neoplasms (Lung Cancer) 01/2018 - 04/2009
5	Lung Injury 06/2016 - 03/2011
4	Infections 07/2020 - 02/2002
4	Colonic Neoplasms (Colon Cancer) 01/2020 - 08/2002
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 01/2009
4	Sarcoma (Soft Tissue Sarcoma) 07/2013 - 01/2002
3	Disease Progression 01/2022 - 04/2005
3	Pneumonia (Pneumonitis) 01/2022 - 08/2012
3	Carcinogenesis 11/2020 - 11/2006
3	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2019 - 05/2004
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2007 - 09/2005
2	COVID-19 11/2020 - 07/2020
2	Fibrosarcoma 01/2019 - 01/2002
2	Genomic Instability 08/2017 - 07/2014

Drug/Important Bio-Agent (IBA)

21	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2003
15	Proteins (Proteins, Gene)FDA Link 10/2020 - 06/2002
12	Immune Checkpoint InhibitorsIBA 01/2022 - 09/2013
12	Biological ProductsIBA 01/2019 - 09/2004
10	AntigensIBA 01/2019 - 05/2010
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2012 - 02/2002
9	MicroRNAs (MicroRNA)IBA 01/2019 - 04/2010
8	Temozolomide (Temodar)FDA LinkGeneric 11/2021 - 09/2004
8	InterferonsIBA 01/2021 - 11/2008
8	CytokinesIBA 09/2016 - 12/2007
7	B7-H1 AntigenIBA 01/2022 - 02/2014
6	Interferon Type IIBA 01/2022 - 11/2014
6	Therapeutic UsesIBA 10/2020 - 07/2009
6	Fluorouracil (Carac)FDA LinkGeneric 01/2014 - 01/2003
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2014 - 01/2003
5	PolymersIBA 01/2022 - 01/2016
5	Neoplasm Antigens (Tumor Antigens)IBA 11/2021 - 01/2007
5	Peptides (Polypeptides)IBA 01/2021 - 01/2004
5	Amifostine (Ethyol)FDA LinkGeneric 02/2013 - 01/2002
5	Complementary DNA (cDNA)IBA 09/2004 - 02/2002
4	Pharmaceutical PreparationsIBA 01/2022 - 01/2007
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 05/2010
4	veliparibIBA 09/2014 - 08/2010
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 09/2014 - 08/2010
4	Prostate-Specific Antigen (Semenogelase)IBA 05/2010 - 08/2004
4	Hydroxyurea (Hydrea)FDA LinkGeneric 04/2008 - 01/2003
4	AngiostatinsIBA 12/2002 - 01/2002
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 12/2004
3	LipidsIBA 01/2022 - 04/2009
3	CholesterolIBA 01/2022 - 04/2009
3	Phosphotransferases (Kinase)IBA 01/2022 - 11/2003
3	Alkylating AgentsIBA 11/2021 - 09/2004
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2021 - 01/2014
3	Interferon-gamma (Interferon, gamma)IBA 01/2019 - 05/2009
3	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2018 - 08/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2014 - 01/2002
3	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 07/2013 - 01/2007
3	Sulfhydryl Compounds (Thiols)IBA 02/2013 - 01/2002
3	N-(2-mercaptoethyl)-1,3-diaminopropaneIBA 02/2013 - 01/2002
3	Oncogene Proteins (Oncogene Protein)IBA 12/2012 - 04/2009
3	Green Fluorescent ProteinsIBA 03/2011 - 05/2004
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2007 - 02/2006
2	NivolumabIBA 01/2022 - 10/2021
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2022 - 11/2014
2	Cytotoxins (Cytolysins)IBA 12/2021 - 01/2017
2	CDC2 Protein Kinase (Protein p34cdc2)IBA 11/2021 - 01/2019
2	Butyrates (Butyrate)IBA 01/2021 - 11/2020
2	pembrolizumabIBA 12/2020 - 01/2018
2	Metal-Organic FrameworksIBA 10/2020 - 01/2016
2	VaccinesIBA 10/2020 - 07/2016
2	LigandsIBA 01/2020 - 05/2009
2	MethyltransferasesIBA 01/2019 - 01/2018
2	Small Interfering RNA (siRNA)IBA 01/2019 - 01/2014
2	Oxygen (Dioxygen)IBA 01/2019 - 09/2013
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 06/2010
2	SurvivinIBA 01/2018 - 10/2016
2	Emodin (Archin)IBA 01/2018 - 10/2016
2	O-(6)-methylguanineIBA 01/2018 - 07/2007
2	Phenobarbital (Luminal)FDA Link 08/2017 - 01/2005

Therapy/Procedure

83	Radiotherapy 01/2022 - 05/2002
78	Therapeutics 01/2022 - 02/2002
26	Immunotherapy 01/2022 - 07/2009
25	Drug Therapy (Chemotherapy) 01/2020 - 01/2003
8	Chemoradiotherapy 01/2017 - 01/2003
6	Image-Guided Radiotherapy 01/2018 - 02/2012
4	Aftercare (After-Treatment) 01/2014 - 01/2007
4	Induction Chemotherapy 01/2014 - 12/2003
3	Radioimmunotherapy 10/2021 - 01/2019
3	Photochemotherapy (Photodynamic Therapy) 12/2016 - 01/2016